


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:03Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407206" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407206</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eid</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">782</journal-id><journal-id journal-id-type="pmc-domain">eid</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407206</article-id><article-id pub-id-type="pmcid-ver">PMC12407206.1</article-id><article-id pub-id-type="pmcaid">12407206</article-id><article-id pub-id-type="pmcaiid">12407206</article-id><article-id pub-id-type="pmid">40867072</article-id><article-id pub-id-type="doi">10.3201/eid3109.250093</article-id><article-id pub-id-type="publisher-id">25-0093</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Pediatric Case Report and Overview of Autochthonous Tick-Borne Encephalitis, Belgium</subject></subj-group></article-categories><title-group><article-title>Pediatric Case Report and Overview of Autochthonous Tick-Borne Encephalitis, Belgium</article-title><alt-title alt-title-type="running-head">Autochthonous Tick-Borne Encephalitis, Belgium</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>De Langhe</surname><given-names initials="J">Justine</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sourbron</surname><given-names initials="J">Jo</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Herreweghe</surname><given-names initials="R">Robbe</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Esbroeck</surname><given-names initials="M">Marjan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vercauteren</surname><given-names initials="K">Koen</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Block</surname><given-names initials="T">Tessa</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coppens</surname><given-names initials="J">Jasmine</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jansen</surname><given-names initials="D">Daan</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van den Bossche</surname><given-names initials="D">Dorien</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Staelens</surname><given-names initials="V">Veerle</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Schryver</surname><given-names initials="S">Sarah</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Van Acker</surname><given-names initials="J">Jos</given-names></name></contrib><aff>Author affiliations: Ghent University Hospital, Ghent, Belgium (J. De Langhe); Ghent University Faculty of Medicine and Health Sciences, Ghent (J. De Langhe, R. Van Herreweghe); University Hospital KU Leuven, Leuven, Belgium (J. Sourbron); Ghent University Hospital Center for Medical Genetics, Ghent (J. Sourbron); Institute of Tropical Medicine Antwerp, Antwerp, Belgium (M. van Esbroeck, K. Vercauteren, T. de Block, J. Coppens, D. Jansen, D. Van den Bossche); AZ Sint-Lucas Gent, Ghent (V. Staelens, S. De Schryver, J. Van Acker);</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Jos Van Acker, Laboratory of Microbiology, AZ Sint-Lucas Gent, Groenebriel 1, 9000 Gent, Belgium; email: <email xlink:href="Jos.VanAcker@azstlucas.be">Jos.VanAcker@azstlucas.be</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>31</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496169</issue-id><fpage>1868</fpage><lpage>1870</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="25-0093.pdf"/><abstract><p>Prevalence of tick-borne encephalitis (TBE) is increasing in much of Europe. In May 2024, an autochthonous pediatric case of TBE was diagnosed in a 6-year-old girl in Belgium. Clinicians should recognize the symptoms and signs of TBE infections and consider this disease in patients with unexplained neurologic symptoms, regardless of travel history.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>tick-borne encephalitis</kwd><kwd>tick-borne encephalitis virus</kwd><kwd>viruses</kwd><kwd>vector-borne infections</kwd><kwd>meningitis/encephalitis</kwd><kwd>ticks</kwd><kwd>Belgium</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Tick-borne encephalitis (TBE) is a disease of the central nervous system (CNS) caused by TBE virus (TBEV). TBEV is endemic in regions from Europe to the Far East, where ixodid ticks act as vectors (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>&#8211;<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). TBEV has 3 main subtypes: European, Siberian, and Far Eastern (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>&#8211;<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). </p><p>Since 1973, TBE incidence has increased by nearly 400% in Europe, excluding Portugal and Belgium. TBE is mainly transmitted from late spring to early autumn, and spread is linked to global warming (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>&#8211;<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). TBEV infection can also occur by consumption of unpasteurized milk products from infected livestock (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>,<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>).</p><p>Clinical course and outcomes vary by TBEV subtype. The European subtype often causes a biphasic illness. Up to 10% of TBE patients develop pareses from myelitis, and the mortality rate is 0.5%&#8211;2%. Symptoms begin 8 days after tick bite (incubation range 4&#8211;28 days) with a nonspecific febrile illness (viremic phase), which resolves before potentially progressing to CNS inflammation 2&#8211;8 days later (neurotrophic phase). Neurologic symptoms include meningitis and meningoencephalitis, typically lasting 7&#8211;10 days (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>,<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). Preventive measures are essential, because no effective treatment exists (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>).</p><p>According to the literature available through August 2024, in Belgium, 8 nonautochthonous (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>) and 3 autochthonous (<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>) TBE cases had occurred in adults. We report an autochthonous pediatric TBE case in Belgium and compare that case to the 3 autochthonous TBE cases in adults.</p><p>A 6-year-old girl was brought for care with a 6-day history of fever, diarrhea, and myalgia. She had returned from Thailand 3 weeks earlier and engaged in several outdoor activities after her return to Belgium. A clinical examination did not identify a cause for the fever. Blood tests showed mild thrombocytopenia, leukopenia, and elevated creatine kinase (CK) (<xref rid="T1" ref-type="table">Table</xref>). An infectious serology search focused on common infections in Thailand. Results of testing of a urine sample and nasopharyngeal swab specimen were negative. A stool sample showed the presence of <italic toggle="yes">Salmonella enterica</italic> serovar Bareilly and <italic toggle="yes">Campylobacter jejuni</italic>; azithromycin was initiated for 3 days. During her 5-day hospital stay, the patient showed clinical improvement, and her fever resolved.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table</label><caption><title>Details of autochthonous tick-borne encephalitis cases in a child compared with 3 previous cases in adults, Belgium*</title></caption><table frame="hsides" rules="groups"><col width="87" span="1"/><col width="90" span="1"/><col width="98" span="1"/><col width="90" span="1"/><col width="115" span="1"/><thead><tr><th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Characteristic</th><th valign="bottom" colspan="3" align="center" scope="colgroup" rowspan="1">Patient no. from 2021 report (<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>)<hr/></th><th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Case report from 2024 (this study)</th></tr><tr><th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">1</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">3</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age of onset, y/sex<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48/F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59/M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58/M<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6/F<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tick bite&#8224;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 weeks before symptom onset<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 weeks before symptom onset<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Multiple tick bites in the weeks before symptom onset<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">No observed tick bite, but increased outdoor&#8232; activities<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Likely site of tick bite, postal code (province)&#8225;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Oostkamp, 8020 (West Flanders)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Lille, 2275 (Antwerp)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Wanze, 4520 (Li&#232;ge)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Evergem, 9940 (East Flanders)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Signs/symptoms</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> During first (viremic) phase</td><td valign="top" align="center" rowspan="1" colspan="1">Myalgia, fever</td><td valign="top" align="center" rowspan="1" colspan="1">Fever, fatigue, myalgia, headache</td><td valign="top" align="center" rowspan="1" colspan="1">Dyspnea, cough, fever</td><td valign="top" align="center" rowspan="1" colspan="1">Recurrent fever, diarrhea, anorexia, arthralgia (ankles, hands and wrists), myalgia, ophthalmalgia, cervicalgia</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> During second (neurotrophic) phase</td><td valign="top" align="center" rowspan="1" colspan="1">Asthenia, tremor, drowsiness, fever, peripheral facial palsy, brachial weakness, nuchal rigidity</td><td valign="top" align="center" rowspan="1" colspan="1">Fever, fatigue, myalgia, headache, paraparesis, signs of meningitis,<break/>severe motor polyradiculitis</td><td valign="top" align="center" rowspan="1" colspan="1">Recurrent fever, severe and persistent headaches, weakness, diarrhea, anorexia</td><td valign="top" align="center" rowspan="1" colspan="1">Spiking fever, photophobia, vomiting, agitated behavior, fatigue, myalgia, arthralgia, diarrhea</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> At follow-up (time)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Weakness of right arm, loss of cognitive function, inability to concentrate, fatigue, tremor (&#8776;2 mo)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Improved motor skills 9 mo after hospitalization (wheelchair at discharge)<break/>(9 mo)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Occasional headaches, otherwise recovered<break/>(&#8776;2 mo)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">No residual symptoms<break/>(6 mo)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sample type (no. days after symptom onset)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5), CSF (6)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (20), CSF (18)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (2), serum (18)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5), serum (17), CSF (17), serum (19), serum (26)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Flavivirus IFA serum (no. days after symptom onset)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5): IgM, TBEV+; IgG, TBEV+</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (20): IgM, TBEV+; IgG, TBEV+</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (2): IgM, TBEV&#8211;; IgG, TBEV&#8211;. Serum (18): IgM, TBEV+; IgG, TBEV+</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5): IgM, TBEV&#8211;; IgG, TBEV&#8211;. Serum (17): IgM, TBEV+ (&gt;1/80); IgG, TBEV+ (&gt;1/80). Serum (26): IgM, TBEV+ (&gt;1/80); IgG, TBEV+ (&gt;1/80)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Flavivirus IFA CSF (days after symptom onset)</td><td valign="top" align="center" rowspan="1" colspan="1">CSF (6): IgM, TBEV+;<break/>IgG, TBEV+</td><td valign="top" align="center" rowspan="1" colspan="1">CSF (18): IgM, TBEV+; IgG, TBEV+</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">CSF (17): IgM, TBEV+; IgG, ND (sample too small for both Ig types)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PRNT<sub>90</sub> titer (no. days after symptom onset)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5): 1:25; CSF (6): ND</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (20): 1:60; CSF (18): ND</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (2): ND; serum (18): 1:194</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (26): 1:204</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> rRT-PCR (no. days after symptom onset)</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5): ND; CSF (6): ND</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (20): ND; CSF (18): ND</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (2): +; serum (18): ND</td><td valign="top" align="center" rowspan="1" colspan="1">Serum (5): + (Ct 36.27); serum (17): ND; CSF (17): ND; serum (19): ND; serum (26): ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TBEV RNA sequencing (serum)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">European subtype TBEV</td></tr></tbody></table><table-wrap-foot><p>*Additional case characteristics are provided in <xref rid="SD1" ref-type="supplementary-material">Appendix</xref> Table 2. CSF, cerebrospinal fluid; Ct, cycle threshold; IFA, indirect fluorescent antibody; ND, not determined; PRNT<sub>90</sub>, 90% plaque reduction neutralization test; rRT-PCR, real-time reverse transcription PCR; TBEV, tick-borne encephalitis virus; +,&#160;present/positive; &#8211;,&#160;absent/negative.
&#8224;Early removal of the tick might not prevent encephalitis &#8203;(<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>)&#8203;. Approximately 30% of cases occur without a reported tick bite &#8203;(<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>,<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>)&#8203;.
&#8225;Locations show no clear proximity (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref> Figure 3).</p></table-wrap-foot></table-wrap><p>Four days after discharge, the girl was readmitted because of recurrent fever for 1 day and arthralgia. Additional blood results showed no anomalies. On day 4 of readmission, meningeal signs appeared, and blood tests showed leukocytosis. Extensive imaging showed no anomalies. A lumbar puncture showed cerebral spinal fluid (CSF) leukocytosis, prompting intravenous cefotaxime. Extensive serology testing was performed. After 7 days of intravenous cefotaxime treatment, TBEV IgM was detected in CSF. The patient, whose symptoms resolved, was discharged. Follow-up consultations indicated favorable recovery without residual symptoms. A brain magnetic resonance imaging scan showed no cerebral injuries.</p><p>We compared the clinical course of this patient to those of the 3 previous autochthonous TBEV cases in Belgium (<xref rid="T1" ref-type="table">Table</xref>). We noted no geographic links between those 3 cases and the pediatric case we report. In all cases, a biphasic course was observed. In 2 of the previous cases, long-term neurologic sequelae were documented several months postinfection; however, we did not observe such sequelae in our case. In cases with persistent neurological deficits, paresis was already evident during the neurotrophic phase, consistent with the 10% of TBE patients who develop paresis as a result of myelitis.</p><p>We observed a biphasic course, observed in 75% of TBE cases (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>&#8211;<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>), in this patient. Serum CK levels were also elevated (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). Some TBE patients have myalgia/myositis, and up to one third have elevated serum CK levels (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>), yet the clinical relevance is still unclear. After the patient had a symptom-free interval, fever recurred, and meningitis was confirmed. TBEV IgM was detected in serum and CSF. Testing for Japanese encephalitis was initiated because of the patient&#8217;s travel history; TBEV testing was included in that panel.</p><p>Given the incubation range of 4&#8211;28 (median 8) days (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>,<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>), we cannot exclude possible TBEV infection in Thailand. However, no TBE cases have been reported in Thailand (<xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>). Moreover, sequencing of the TBEV RNA from a serum sample identified the European subtype, suggesting infection acquired in Europe (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>). Although no tick bite was reported for this patient, her increased outdoor activities posed a substantial risk; tick bites go unnoticed in about one third of TBE cases (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>).</p><p>A rare transmission route of TBEV (1% of all cases) is through consuming unpasteurized milk from infected livestock (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>). This patient consumed unpasteurized cow&#8217;s milk &gt;2 weeks before symptoms appeared; however, the Federal Agency for Food Chain Safety in Belgium investigated the identified producer&#8217;s milk and found no TBEV RNA.</p><p>Of note, the patient&#8217;s dog had recently been euthanized because of a suspected stroke. Neurologic signs such as ataxia, plegia/paresis, cranial nerve deficits, and seizures have been described in TBEV-infected dogs (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). However, postmortem investigations were not performed because the animal was cremated.</p><p>Because most (70%&#8211;98%) TBEV infections are asymptomatic, prevalence of TBEV infections is presumably underestimated (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>,<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>). Clinicians should recognize the signs and symptoms of TBEV infection and consider TBE in patients with unexplained neurologic symptoms, particularly a biphasic course (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>).</p><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Appendix</title><p>Additional information for pediatric case report and overview of autochthonous tick-borne encephalitis, Belgium.</p></caption><media xlink:href="25-0093-Techapp-s1.pdf" id="d67e458" position="anchor" orientation="portrait"/></supplementary-material></body><back><ack><title>Acknowledgments</title><p>We thank the patient and their parents for participating in our study, sharing their medical histories, and allowing us to publish these data. We thank Sandra Coppens and Kadrie Ramadan for their technical support.</p><p>All authors made substantial contributions to the conception and design of the study; data acquisition, analysis, and interpretation; and drafting of the article.</p><p>J.S. served as a consultant or speaker for UCB and Bright Minds Biosciences and as a member of the medical advisory board for UCB. </p></ack><fn-group><fn fn-type="other"><p><italic toggle="yes">Suggested citation for this article</italic>: De Langhe J, Sourbron J, Van Herreweghe R, van Esbroeck M, Vercauteren K, de Block T, et al. Pediatric case report and overview of autochthonous tick-borne encephalitis, Belgium. Emerg Infect Dis. 2025 Sep [<italic toggle="yes">date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid3109.250093" ext-link-type="uri">https://doi.org/10.3201/eid3109.250093</ext-link></p></fn></fn-group><bio id="d67e474"><p>Ms. De Langhe is a pediatrician in training at the University of Ghent. </p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Palyga-Bysiecka</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kr&#281;cisz</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Szczepa&#324;ska</surname><given-names>B</given-names></string-name>. <article-title>Clinical course and neurological sequels after tick-borne encephalitis in children - case report.</article-title><source>Ann Agric Environ Med</source>. <year>2022</year>;<volume>29</volume>:<fpage>162</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.26444/aaem/133206</pub-id><pub-id pub-id-type="pmid">35352922</pub-id></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Riccardi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Antonello</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Luzzati</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zajkowska</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Di Bella</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giacobbe</surname><given-names>DR</given-names></string-name>. <article-title>Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment.</article-title><source>Eur J Intern Med</source>. <year>2019</year>;<volume>62</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30678880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejim.2019.01.004</pub-id></mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lindquist</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vapalahti</surname><given-names>O</given-names></string-name>. <article-title>Tick-borne encephalitis.</article-title><source>Lancet</source>. <year>2008</year>;<volume>371</volume>:<fpage>1861</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">18514730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60800-4</pub-id></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cesaroni</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Frattini</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lecis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bonvicini</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bartolomeo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rizzi</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Tick-borne encephalitis in a 6-year-old patient: a case report.</article-title><source>Neurohospitalist</source>. <year>2024</year>;<volume>14</volume>:<fpage>64</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">38235031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/19418744231205626</pub-id><pub-id pub-id-type="pmcid">PMC10790612</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="book"><collab>National Reference Center for TBEV</collab>. Tick-borne encephalitis virus, List of confirmed human cases of acute TBE, 2012&#8211;2017. Antwerp: The Center; <year>2017</year>.</mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stoefs</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heyndrickx</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>De Winter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Coeckelbergh</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Willekens</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alonso-Jim&#233;nez</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Autochthonous cases of tick-borne encephalitis, Belgium, 2020.</article-title><source>Emerg Infect Dis</source>. <year>2021</year>;<volume>27</volume>:<fpage>2179</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.3201/eid2708.211175</pub-id><pub-id pub-id-type="pmid">34111382</pub-id><pub-id pub-id-type="pmcid">PMC8314842</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bogovi&#269;</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lotri&#269;-Furlan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ogrinc</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Av&#353;i&#269; &#381;upanc</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kastrin</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Elevated levels of serum muscle enzymes in the initial phase of tick-borne encephalitis.</article-title><source>Infect Dis (Lond)</source>. <year>2024</year>;<volume>56</volume>:<fpage>504</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/23744235.2024.2335349</pub-id><pub-id pub-id-type="pmid">38564769</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Raksakoon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Potiwat</surname><given-names>R</given-names></string-name>. <article-title>Current arboviral threats and their potential vectors in Thailand.</article-title><source>Pathogens</source>. <year>2021</year>;<volume>10</volume>:<fpage>80</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens10010080</pub-id><pub-id pub-id-type="pmid">33477699</pub-id><pub-id pub-id-type="pmcid">PMC7831943</pub-id></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Buczek</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Buczek</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Buczek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wysoki&#324;ska-Miszczuk</surname><given-names>J</given-names></string-name>. <article-title>Food-borne transmission of tick-borne encephalitis virus&#8212;spread, consequences, and prophylaxis.</article-title><source>Int J Environ Res Public Health</source>. <year>2022</year>;<volume>19</volume>:<fpage>1812</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph19031812</pub-id><pub-id pub-id-type="pmid">35162837</pub-id><pub-id pub-id-type="pmcid">PMC8835261</pub-id></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kleeb</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Golini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Beckmann</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Torgerson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Steffen</surname><given-names>F</given-names></string-name>. <article-title>Canine tick-borne encephalitis: clinical features, survival rate and neurological sequelae: a retrospective study of 54 cases (1999&#8211;2016).</article-title><source>Front Vet Sci</source>. <year>2021</year>;<volume>8</volume>:<elocation-id>782044</elocation-id>. <pub-id pub-id-type="doi">10.3389/fvets.2021.782044</pub-id><pub-id pub-id-type="pmid">34859094</pub-id><pub-id pub-id-type="pmcid">PMC8631292</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>